HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
First-line Treatment of Advanced Pancreatic Cancer
Conditions
First-line Treatment of Advanced Pancreatic Cancer
Trial Timeline
Jun 13, 2023 → Dec 30, 2025
NCT ID
NCT05751850About HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for First-line Treatment of Advanced Pancreatic Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05751850. Target conditions include First-line Treatment of Advanced Pancreatic Cancer.
What happened to similar drugs?
0 of 2 similar drugs in First-line Treatment of Advanced Pancreatic Cancer were approved
Approved (0) Terminated (0) Active (2)
🔄Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05751850 | Phase 3 | Recruiting |
Competing Products
2 competing products in First-line Treatment of Advanced Pancreatic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine | Jiangsu Hengrui Medicine | Phase 3 | 47 |
| HRS-4642 + AG + HRS-4642 placebo + AG | Jiangsu Hengrui Medicine | Phase 3 | 47 |